DNDN -- Doc, docetaxel had already been approved for breast cancer, so a lot of patients in both arms were able to take it off label. In the 9901 trial, 37% of the pts in the Provenge arm got docetaxel, while 49% of the control arm took it. Supposedly, the patients in the Provenge arm averaged fewer cycles of docetaxel than those in the control arm.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.